A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06921850
·
clinicaltrials.gov ↗
PHASE3
Phase
RECRUITING
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Hidradenitis Suppurativa
Interventions
DRUG:
Bimekizumab
Sponsor
UCB Biopharma SRL